TNG:EPA
Transgene SA
€0,68
arrow_downward
-0,73%(-0,0050) 1 HR
19 Okt, 17.35.04 GMT+2 · EUR
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk TNG...
Pembukaan
€0,69
Tinggi
€0,70
Rendah
€0,68
Kapitalisasi pasar
189,70 jt
Volume rata-rata
111,65 rb
Volume
53,57 rb
Harga tinggi dalam 52 minggu terakhir
€1,50
Harga rendah dalam 52 minggu terakhir
€0,68
EPS
-€0,17
Saham beredar
278,56 jt
Jumlah karyawan
152
Pembukaan
€0,69
Tinggi
€0,70
Rendah
€0,68
Kapitalisasi pasar
189,70 jt
Volume rata-rata
111,65 rb
Volume
53,57 rb
Harga tinggi dalam 52 minggu terakhir
€1,50
Harga rendah dalam 52 minggu terakhir
€0,68
EPS
-€0,17
Saham beredar
278,56 jt
Jumlah karyawan
152
Artikel berita
Dari sumber web dan partner berita
Katadata.co.id
·
18 jam yang lalu
Wall Street Berguguran, Dow Jones Anjlok 2,14% Tertekan Saham Teknologi dan AI
Pluang
·
8 jam yang lalu
S&P 500 hadapi sesi penting di tengah kekhawati...
XTB
·
3 hari yang lalu
Dow Jones Naik, Nasdaq dan Saham AI Turun
InvestorTrust
·
18 jam yang lalu
Wall Street Berusaha Bangkit, Dow Futures Menguat Lebih 100 Poin
Profil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Tentang Transgene SA